These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8859617)

  • 1. Thromboembolic events with paclitaxel.
    Chan AT; Yeo W; Leung WT; Johnson PJ
    Clin Oncol (R Coll Radiol); 1996; 8(2):133. PubMed ID: 8859617
    [No Abstract]   [Full Text] [Related]  

  • 2. Paclitaxel premedication regimens.
    Boehm DK; Maksymiuk AW
    J Natl Cancer Inst; 1996 Apr; 88(7):463-5. PubMed ID: 8618242
    [No Abstract]   [Full Text] [Related]  

  • 3. Hypersensitivity reaction to paclitaxel: nursing interventions.
    Myers JS
    Clin J Oncol Nurs; 2000; 4(4):161-3. PubMed ID: 11261096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Paclitaxel hypersensitivity reactions in patients with advanced ovarian carcinoma].
    Kobierski J; Majdak E; Mielcarek P; Emerich J
    Ginekol Pol; 2002 Nov; 73(11):1015-20. PubMed ID: 12722392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cetirizine versus diphenhydramine in the prevention of chemotherapy-related hypersensitivity reactions.
    Durham CG; Thotakura D; Sager L; Foster J; Herrington JD
    J Oncol Pharm Pract; 2019 Sep; 25(6):1396-1401. PubMed ID: 30419768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypertensive reactions associated with paclitaxel.
    Solimando DA; Phillips ET; Weiss RB; Dawson NA; Diehl LF; Rickles NM
    Cancer Invest; 1996; 14(4):340-2. PubMed ID: 8689429
    [No Abstract]   [Full Text] [Related]  

  • 7. Preliminary experience with a modified premedication protocol that included intravenous diphenhydramine and calcium bromide for the prophylaxis of paclitaxel-related hypersensitivity reactions.
    Sasada S; Hirashima T; Nakamura Y; Takimoto T; Furukawa M; Kobayashi M; Nitta T; Matsui K; Kawase I
    Int J Clin Oncol; 2007 Aug; 12(4):274-8. PubMed ID: 17701006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Taxol].
    Kühnle H
    Zentralbl Gynakol; 1996; 118(10):580. PubMed ID: 8999717
    [No Abstract]   [Full Text] [Related]  

  • 9. Cross-reactivity between paclitaxel and hazelnut: a case report.
    Bukacel DG; Bander R; Ibrahim RB
    J Oncol Pharm Pract; 2007 Mar; 13(1):53-5. PubMed ID: 17621569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Administration of premedication with fexofenadine for paclitaxel-induced hypersensitive reactions in breast cancer patients complicated with closed-angle glaucoma].
    Komatsubara K; Miyoshi K; Kogure Y; Matsuhisa T; Eguchi H
    Gan To Kagaku Ryoho; 2010 Jan; 37(1):107-10. PubMed ID: 20087041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risks and benefits of taxanes in breast and ovarian cancer.
    Michaud LB; Valero V; Hortobagyi G
    Drug Saf; 2000 Nov; 23(5):401-28. PubMed ID: 11085347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.
    Bookman MA; Kloth DD; Kover PE; Smolinski S; Ozols RF
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-13-S19-15. PubMed ID: 9427258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac dysfunction in cancer patients receiving paclitaxel.
    Valdés Olmos RA; ten Bokkel Huinink WW; Hoefnagel CA
    Eur J Nucl Med; 1998 Apr; 25(4):446-7. PubMed ID: 9643974
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer.
    Klaassen U; Wilke H; Strumberg D; Eberhardt W; Korn M; Seeber S
    Eur J Cancer; 1996 Mar; 32A(3):547-9. PubMed ID: 8814705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic effect of pemirolast, an antiallergic agent, against hypersensitivity reactions to paclitaxel in patients with ovarian cancer.
    Yahata H; Saito M; Sendo T; Itoh Y; Uchida M; Hirakawa T; Nakano H; Oishi R
    Int J Cancer; 2006 May; 118(10):2636-8. PubMed ID: 16353140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A phase II clinical study of China-made paclitaxel in the treatment of cancer patients].
    Wu H; Guan Z; Lin T
    Zhonghua Zhong Liu Za Zhi; 1998 Mar; 20(2):148-52. PubMed ID: 10920970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergency. Chemotherapy-induced hypersensitivity reaction.
    Myers JS; Kearney K
    Am J Nurs; 2000 Apr; 100(4):53-4. PubMed ID: 10776352
    [No Abstract]   [Full Text] [Related]  

  • 18. [Taxol (paclitaxel) as second-line therapy in breast and ovarian cancer].
    Borovik R; Steiner M; Atad J; Sneiderman B; Rosenberg T; Palti S
    Harefuah; 1998 Apr; 134(8):605-8, 671. PubMed ID: 10911422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The feasibility of dexamethasone omission in weekly paclitaxel treatment for breast cancer patients.
    de Castro Baccarin AL; Irene MN; de Iracema Gomes Cubero D; Luz AS; Castro SN; Sordi R; Móz LES; Del Giglio A
    Support Care Cancer; 2019 Mar; 27(3):927-931. PubMed ID: 30069696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute myocardial infarction following paclitaxel administration for ovarian carcinoma.
    Laher S; Karp SJ
    Clin Oncol (R Coll Radiol); 1997; 9(2):124-6. PubMed ID: 9135899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.